While we could not determine causality between insulin and mortality, we highlight a vulnerable population which needs additional resources in the discharge transition period,” the authors wrote.
From 2000 to 2014, the age-standardized incidence of end-stage renal disease (ESRD) attributed to diabetes decreased from 260.2 to 173.9 per 100,000 diabetic population.
A limitation of the industry-funded randomized trial was the high rate of early discontinuation: 43.0% of patients on exenatide and 45.2% of those on placebo.
Patients with diabetes and obesity who had metabolic surgery were matched in a 1:5 ratio to those who received usual care, with incidence of a major cardiovascular event (MACE) as the primary outcome.
The population-based retrospective cohort study included 22,124 type 2 diabetes patients from a British national primary care database, 4,444 of whom had taken dapagliflozin.
The guideline, developed by the Joint British Diabetes Societies for Inpatient Care, noted that many patients taking insulin will know more about their usual regimen than the medical and nursing staff responsible for their care.
For patients without diabetes, predictors of myocardial injury after noncardiac surgery included a casual glucose level of more than 6.86 mmol/L (124 mg/dL) and a fasting glucose level of more than 6.41 mmol/L (116 mg/dL).
probably indicates a more accelerated intimal hyperplasia, greater degree of vascular inflammation and/or endothelial dysfunction, and increased plaque vulnerability in insulin-treated diabetic patients, and highlights the need for
Risk of atrial fibrillation increased with worse glycemic control and renal complications. Among patients with normoalbuminuria, researchers found no excess risk of atrial fibrillation with an HbA1c less than 9.7% for men or 8.8% for women.
Compared to young adults without diabetes, those with diabetes were more likely to have obesity, elevated lipids, or hypertension and were less likely to report being physically active or consuming a healthy diet.